A revolutionary new asset paradigm is sweeping across the globe: silent patents, massive real estate properties, and even strings of unrealized data are coming "alive" through blockchain technology, achieving 24/7 uninterrupted global circulation and financing. This is the financial revolution brought by RWA (Real World Asset) tokenization.

On the morning of September 22, in Jianye District, Nanjing, a grand opening ceremony themed "Empowering Real Economy: Anchoring Trillion-Dollar Assets, Opening New Era of On-Chain Flow" was held. The world's first RWA technology base built by IVD MEDICAL (01931) - the ETHK Building (IVD MEDICAL Building) - was officially launched. This marks a crucial step for China in the large-scale technical implementation of RWA, making the era of asset "passive income" a reality.

**China's RWA Industry Reaches Physical Implementation Milestone, Nanjing Births New Tech Landmark**

While RWA is not a new concept, its large-scale implementation has consistently faced dual challenges of technical infrastructure and compliance frameworks. The ETHK Building launched by IVD MEDICAL represents a physical solution to these challenges.

According to the company's September 19 announcement, ETHK Building has a total construction area of approximately 70,000 square meters, with the main building spanning 35,000 square meters, making it currently the world's largest and most comprehensive RWA physical R&D and innovation base. It serves not only as the core vehicle for IVD MEDICAL's "ETHK On-Chain Financial Ecosystem Strategy" but is also designed as dual composite infrastructure: both a physical R&D and collaborative innovation center and a trusted technology R&D and output base.

The building houses world-class R&D laboratories, data centers, and testing environments, expected to gather over 5,000 technical experts and engineers in the future, forming one of the strongest R&D teams in the global RWA field. Its technical positioning is clear - dedicated to providing enterprises and institutional clients with comprehensive one-stop digital technology solutions covering the full lifecycle of physical assets.

Choosing Nanjing as the landing city reflects IVD MEDICAL's far-reaching strategic considerations. The Yangtze River Delta region is one of China's core biopharmaceutical industry clusters, with an industry scale accounting for 1/8 of the national total and new drug approvals representing 1/3 of the national figure. The region's rich industrial resources, university research advantages, and Jiangsu Free Trade Zone's biopharmaceutical full-industry-chain open innovation policies provide the ideal testing ground for RWA technology applications in vertical sectors like medical assets.

As Pan Aping, Party Secretary of Tianjin Pharmaceutical Group, noted in his address: "The rise of this building is not just the birth of architecture, but a symbol of the integrated development of the biopharmaceutical industry and digital technology."

Professor Gu Jianqin, Dean of Southern University of Science and Technology Hospital, further elaborated on its industry value: "The platform created by IVD MEDICAL has opened channels and established chains for financing and global deployment of many excellent drug R&D projects."

**Breaking Asset Liquidity Bottlenecks, RWA Tokenization Reshapes Value Realization Models**

The core value of RWA tokenization lies in breaking the liquidity dilemma of high-quality assets, innovating enterprise financing channels, and accelerating global market deployment. IVD MEDICAL's innovative "ETHK Global RWA Trading - Exchange within Exchange" model is filling gaps in China's RWA service chain.

This model aims to build a B2B inter-institutional trading ecosystem covering multiple industry sectors, providing one-stop solutions for asset screening, structural design, compliant issuance, and liquidity management by establishing vertical RWA exchanges for leading enterprises across various industries.

Dr. Daniel Yu, Chairman of ETHK Group and CEO of IVD Capital, explained the vision in his address: "From fiat currency tokenization to asset tokenization, and then to physical tokenization, we are committed to building a real-world token economy ecosystem, using tokens as new value carriers to achieve more efficient on-chain value circulation and smarter value collaboration."

This model's value is particularly prominent in the healthcare sector. Dr. Qian Xueming, Chairman of the Board of TriBiotica, pointed out: "New drug development has long cycles, financing difficulties, and major overseas expansion challenges. Through IVD MEDICAL's on-chain RWA digital platform, we can package innovative drug pipeline IP into US SPVs for new-type financing, providing us with valuable capital support."

**Perfecting RWA Service Ecosystem, "Exchange within Exchange" Model Enters Large-Scale Replication Phase**

Following the September 16 announcement of partnering with Renhe International to create the world's first OTC vertical RWA exchange, IVD MEDICAL signed agreements with four more important partners during this opening ceremony, marking the entry of its "exchange within exchange" model into the large-scale replication phase.

During the signing ceremony, IVD MEDICAL entered strategic cooperation agreements with Suzhou TriBiotica Pharmaceutical Group, Shenzhen Origin Life Sciences Co., Ltd., Jiangsu Mailink Technology Industry Development Group, and Beijing Guofeng Law Firm. These partnerships cover key areas including pharmaceutical R&D, life sciences, technology industry, and legal compliance.

The collaboration with TriBiotica Group particularly involves RWA tokenization of innovative drug pipeline assets, covering six core innovative drug pipeline assets including TST003 and TST005, with a total valuation exceeding $1.5 billion, representing the most cutting-edge R&D directions and high technical barriers in global oncology treatment.

Wang Hongyong, General Manager of Shenzhen Origin Life Sciences Co., Ltd., stated: "This cooperation represents an important attempt at combining biomedicine with digital finance. IVD MEDICAL's digital trading platform will provide global liquidity and financing channels for our innovative drug assets. This model not only reduces the capital threshold for new drug R&D but also provides possibilities for global investors to participate in innovation and share value."

Another important segment of the event was the release of the "RWA Protocol White Paper." ETHK CTO Mike pointed out in his presentation that current financial systems face three major technical bottlenecks: low settlement efficiency, insufficient transparency, and fragmented compliance. Addressing these challenges, the RWA protocol focuses on creating underlying protocols designed for real-world asset issuance and trading, featuring three characteristics: verifiability, compliance, and scalability.

"The RWA protocol is not just a technical standard; it represents the vision of next-generation financial infrastructure," Mike emphasized. "It makes atomic settlement in capital markets possible and enables truly transparent, compliant, and efficient cross-border asset allocation."

**Empowering Global Real Economy, Opening Era of High-Quality Asset "Passive Income"**

IVD MEDICAL's "ETHK On-Chain Financial Ecosystem Strategy" essentially does something of great social value: empowering the real economy, helping Chinese enterprises efficiently go global, and gaining global value discovery and capital support.

The core of this empowerment lies in the "altruistic" philosophy. Through RWA tokenization, IVD MEDICAL not only helps asset holders activate existing assets but also provides global investors with new channels for allocating high-quality assets, ultimately benefiting end users - enabling patients to access innovative drug treatments faster and consumers to experience cutting-edge technology products earlier.

As Wang Hongyong stated: "Origin Life's R&D pipeline, supported by RWA and resources, will accelerate and expand clinical trials and market launch processes, enabling more patients to benefit from cutting-edge treatment solutions sooner, truly realizing the mission of innovation benefiting life."

IVD MEDICAL's strategic vision aligns highly with national policy directions. Since 2025, multiple national departments have continuously issued policies encouraging market-oriented operations and securitization exploration of intellectual property. The September 11 "Reply to Implementation Plan for Comprehensive Reform Pilot of Market-oriented Allocation of Production Factors in Some Regions Nationwide" issued by the State Council repeatedly mentions marketization and securitization of intellectual property, supporting "exploration of standardized new application models such as intellectual property securitization, intellectual property insurance, and intellectual property pledge."

Globally, the RWA market is experiencing explosive growth. According to joint predictions by Boston Consulting Group (BCG) and Singapore Digital Securities Exchange (ADDX), the global RWA market will reach $16.1 trillion by 2030, accounting for 10% of global GDP. Through the construction of ETHK Building as a physical base, IVD MEDICAL is seizing the initiative in this global competition.

The completion of ETHK Building represents not just the birth of a building, but the establishment of a new financial paradigm. It symbolizes China's innovative strength in the integration of blockchain and real economy, representing Chinese enterprises' proactive stance in the global digital finance wave. As more assets achieve "on-chain flow" through RWA, a more open, efficient, and inclusive new era of global asset allocation is emerging. IVD MEDICAL is accelerating this future reality through technological and model innovation, truly opening the era of high-quality asset "passive income."